After an agronomy engineering school (INP-ENSAT, Toulouse), Clément AURIOL specialized in white biotechnology by earning a Ph.D. in microbiology and industrial biocatalysis from INSA Toulouse by working at Metabolic Explorer (CIFRE grant).
Between 2009 and 2016, Clément held different postdoctoral positions in INSA-Toulouse and TWB, always linked with industrial partners.
Since 2016, Clément is a R&D Manager within CINABio, the biotech laboratory of Adisseo, where he is in charge of developing new biotech process, especially for amino acid production.
Sylvio Bengio manages the Scientific programs at Adebiotech, independent Biotechnology think tank. Sylvio holds a PhD in cellular and molecular bioology and has been active in industry through various management positions in Biotechnology and technology supply.
He is a member of the scientific/programming Committee of CFIB2022 Conference and is the main contact for questions related to the scientific agenda.
Fayza DABOUSSI is Scientific Director at TWB, a French public / private industrial biotechnology organization that transitions early stage R&D from academic labs into preindustrial development projects and start-ups. Fayza has 20+ years in research and development using genetic engineering to develop solutions in various fields from health to commodity chemicals. Her expertise stands in human cells as well as in microorganisms (yeasts, microalgae…). Prior to TWB, Fayza was VP Synthetic Biology and Technology at Cellectis SA, a clinical-stage biopharmaceutical company with 20 years of expertise in genome editing where she spent 6 years and Research Director at INRAE to develop synthetic biology in microalgae. Fayza also supports French initiative on biotherapeutics reduction costs through the Toulouse Industrial Biotechnology for Health (TIBH) integrator.
Deputy head of Biologics Research Dpt. Vitry, Head of Protein Science & Technology, Sanofi, France
32 years experience in Pharma R&D
Head of Protein Science & Technology and Deputy Head Biologics Research Vitry,Sanofi
Between 2012 and 2014 global Head of Protein Biotherapeutics. Previously Head of Protein Production during 12 years in Aventis and Sanofi-Aventis (2000 –2012). Group Leader in Biotechnology, Hoechst Marion Roussel, 1988 –2000, (12 years). PhD in 1988 in Cellular and Molecular Biology (University Paris VI, France): Purification, biochemical and immunological characterization of human teeth collagenase, in Protein Chemistry Lab Institut Pasteur of Paris.
Main expertises in R&D on expression and purification/characterization/developability of recombinant proteins and antibodies, Biologics, for Medicinal Chemistry and Biotherapeutics projects for all kind of uses (screening, crystallography, IHC, PK-PD, in vitro and in vivo studies…). Purification of proteins, from mg scale to several grams (DSP). Support to Medicinal Chemistry projects, and development of purification processes for Biologics. Metalloproteinases. Previously project leader of Cardiovascular and Anti-Infective projects.
Philippe holds a PhD in Molecular Biology from the Université Libre de Bruxelles (ULB) obtained in 1993 and a Master in Management de l’Innovation from HEC Saint Louis (Brussels, Belgium) obtained in 1995.
In 1995-1996 Philippe did a post-doctoral research at the University of Edinburgh (UK). During this research he discovered using mouse model the function of the alpha-fetoprotein the major embryonic plasma protein in mammalian development.
During his academic research career he was involved has an inventor in the development of a portfolio of genetic selection patented technologies.
One of these technologies belonging to ULB was licensed to Life technologies and is on the market since 1995 it is today a standard in DNA assembly method: Gateway technology, TOPO cloning. Other technologies were licensed to Sanofi-Pasteur, GSK and Merck to improve biopharmaceutical production.
Since 2013 Philippe is the founder and Chief Scientific Officer of Syngulon a startup focusing on genetic innovations to improve the biocontrol of microbial population using bacteriocins (antimicrobial peptides). Philippe has established several partnerships for the company with academics and industries.
After a PhD in molecular and cellular biology, Georges Pignède has always worked in R&D in private companies. He started his career as a scientist at the pharmaceutical company Mayoly-Spindler and stayed there for almost 10 years. During this period, using many different prokaryotic and eukaryotic expression systems (E. coli, mammalian cells, insect cells, filamentous fungi and yeast), he specialized in the expression of recombinant proteins useful for the screening of chemical compounds or to produce therapeutic enzymes.
He then joined 20 years ago the R&D department of Lesaffre, the world leader for baking yeast, first as a senior researcher in genetics and then as head of the team dedicated to the improvement and development of new strains for all Lesaffre’s businesses.
He is now part of the recently created Biofoundry team to accelerate research processes using the latest innovations in this field.
After an agricultural engineer School in France (Lasalle Beauvais), Alexis RANNOU joined ARD for activities in R&D to extract non digestible sugar for surfactant application (1991-1995). He was after in charge of ARD’s pilot plant (1995-1997).
In 1997 he joined the Soliance company (daughter company of ARD) as technical director.
In 2000 he was named as Deputy General Manager in charge of the industrial production.
In 2007 he was in charge of the innovation team and several global accounts.
In 2014 he joined Givaudan as Operations Director & site manager
Since 2018, he held the position of Head of Operations Strategy in charge of tolling & process development for Givaudan Active Beauty
Simon Trancart is co-founder and CEO of Altar. He earned diplomas from Ecole Centrale Paris (France) and Escola Politécnica da Universidade de São Paulo (Brazil). Previously, Simon held different position at the sugar and bioenergies division of engineering group Fives. In 2013, Simon launched Heurisko, a biotech specialized in microbial fluidics. He co-founded Altar in 2017 that supports strain development in several industrial fields.
Geneticist by training, Gilles Truan joined the CNRS in 1997. His research topic was aimed at understanding enzyme structure function relationships through directed evolution techniques with a special focus on cytochrome P450. He then moved towards understanding the role of protein dynamics in their catalytic function, especially the P450redox partners. In 2011, the team joined the Toulouse Biotech Institute in Toulouse and took a new turn towards synthetic biology. Gilles Truan is now the PI of the Molecular and Metabolic Engineering team (I2M) and Head of the Metabolic Engineering Department. The I2M team is widely recognized in France in the field of synthetic biology. Several projects are now ongoing in this field, leading to the synthesis, by yeast, of several important industrial molecules. Gilles Truan is also the director, with Jean-Loup Faulon, of the National Research Group on Synthetic and Systems Biology (BioSynSys).